Document Detail


Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome.
MedLine Citation:
PMID:  21538144     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The use of metformin throughout gestation by pregnant women with polycystic ovary syndrome (PCOS) significantly reduces the number of first trimester spontaneous abortions and the rate of occurrence of gestational diabetes.
OBJECTIVE: The objective of this study was to investigate the pharmacokinetics and the placental transfer of metformin in pregnant women with PCOS.
PATIENTS AND METHODS: Eight pregnant women with PCOS taking 850 mg metformin every 12 h during the third trimester of pregnancy were evaluated. Maternal blood samples were collected at steady state during the dose interval (0-12 h). Maternal and umbilical cord blood samples were also obtained at delivery. Metformin plasma concentrations were analyzed by high-performance liquid chromatography, and pharmacokinetic parameters were determined using a non-compartmental model. Data are reported as median and minimum and maximum values.
RESULTS: Metformin pharmacokinetic parameters were: t(½), 3.8 (2.8-5.4) h; t(max), 2.0 (0.5-3.0) h; C(max), 1.4 (0.5-2.1) mg/L; C(mean), 0.5 (0.2-0.9) mg/L; AUC(0-12), 6.4 (1.1-9.2) mg h/L; Cl/f, 105 (60-274) L/h; Vd/f, 551 (385-1173) L; median fluctuation, 89 (79-95)%. Umbilical/maternal metformin plasma concentration ratios were 0.7 (0.4-1.3).
CONCLUSION: Metformin oral clearance (Cl/f) had increased in our patients relative to nonpregnant healthy volunteers or diabetic patients. Therefore, lower plasma metformin concentrations were observed for nondiabetic pregnant women with PCOS. Future studies should be conducted to demonstrate the therapeutic efficacy of metformin during pregnancy. Caution is warranted as umbilical/maternal metformin plasma concentrations ratios of around 0.7 require metformin dosage adjustment.
Authors:
Cláudia de Oliveira Baraldi; Vera Lucia Lanchote; Natalícia de Jesus Antunes; Teresa Maria de Jesus Ponte Carvalho; Elaine Christine Dantas Moisés; Elaine Christine Dantes Moisés; Geraldo Duarte; Ricardo Carvalho Cavalli
Related Documents :
21215894 - Treatment and control of peri-parturient metabolic diseases: pregnancy toxemia, hypocal...
24204474 - Correction: semen levels of spermatid-specific thioredoxin-3 correlate with pregnancy r...
21531374 - Severe early-onset preeclampsia is not associated with a change in placental catechol o...
23604704 - Non-obstructive azoospermia and clinical varicocele: therapeutic options.
3670804 - Pathophysiology and prognosis of sudden deafness with special reference to the n1 latency.
16236364 - Clara cell protein 16 concentration in mid-trimester amniotic fluid: association with f...
Publication Detail:
Type:  Journal Article     Date:  2011-05-03
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  67     ISSN:  1432-1041     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-09     Completed Date:  2012-03-20     Revised Date:  2012-04-06    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1027-33     Citation Subset:  IM    
Affiliation:
Department of Gynecology and Obstetrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Female
Fetal Blood
Humans
Hypoglycemic Agents / adverse effects,  blood,  pharmacokinetics*,  therapeutic use
Maternal-Fetal Exchange / drug effects
Metformin / adverse effects,  blood,  pharmacokinetics*,  therapeutic use
Polycystic Ovary Syndrome / drug therapy,  metabolism*
Pregnancy
Pregnancy Complications, Neoplastic / drug therapy,  metabolism*
Pregnancy Trimester, Third / drug effects
Young Adult
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 657-24-9/Metformin
Comments/Corrections
Erratum In:
Eur J Clin Pharmacol. 2012 Mar;68(3):329
Note: Dantes Moisés, Elaine Christine [corrected to Dantas Moisés, Elaine Christine]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low-power 808-nm laser irradiation inhibits cell proliferation of a human-derived glioblastoma cell ...
Next Document:  One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyper...